1. Home
  2. LUCY vs ACXP Comparison

LUCY vs ACXP Comparison

Compare LUCY & ACXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Innovative Eyewear Inc.

LUCY

Innovative Eyewear Inc.

HOLD

Current Price

$0.72

Market Cap

6.7M

Sector

Health Care

ML Signal

HOLD

Logo Acurx Pharmaceuticals Inc.

ACXP

Acurx Pharmaceuticals Inc.

HOLD

Current Price

$1.54

Market Cap

6.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LUCY
ACXP
Founded
2017
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Ophthalmic Goods
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.7M
6.6M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
LUCY
ACXP
Price
$0.72
$1.54
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$95.50
AVG Volume (30 Days)
215.0K
82.4K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
63.39
N/A
EPS
N/A
N/A
Revenue
$2,661,669.00
N/A
Revenue This Year
$175.92
N/A
Revenue Next Year
$205.56
N/A
P/E Ratio
N/A
N/A
Revenue Growth
62.65
N/A
52 Week Low
$0.65
$1.33
52 Week High
$2.24
$8.34

Technical Indicators

Market Signals
Indicator
LUCY
ACXP
Relative Strength Index (RSI) 44.94 53.16
Support Level $0.66 $1.36
Resistance Level $1.17 $1.75
Average True Range (ATR) 0.06 0.09
MACD 0.00 0.02
Stochastic Oscillator 50.72 70.20

Price Performance

Historical Comparison
LUCY
ACXP

About LUCY Innovative Eyewear Inc.

Innovative Eyewear Inc is engaged in developing and selling eyeglasses and sunglasses, which are designed to allow customers to remain connected to their digital lives, while also offering prescription eyewear and sun protection. Its products include Lucyd Lyte, Nautica, Eddie Bauer, Lucyd Armor line, and Reebok. The firm derive substantially all of its revenue from the sale of smart glasses and custom lenses.

About ACXP Acurx Pharmaceuticals Inc.

Acurx Pharmaceuticals Inc is a late-stage biopharmaceutical company focused on developing a new class of small-molecule antibiotics for difficult-to-treat bacterial infections. Its approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram-positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and Gram-positive bacterial cell death. Its research and development pipeline includes antibiotic product candidates targeting Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and drug-resistant Streptococcus pneumoniae and B. anthracis. It operates in a single segment.

Share on Social Networks: